



# Clinical Infectious Diseases



## Subscriptions

A subscription to *Clinical Infectious Diseases* comprises 24 issues. Prices include dispatch by Standard Air. Airmail rates are available on request. *Clinical Infectious Diseases* Advance Access contains papers that have recently been accepted but have not yet been included within an issue. Advance Access is updated daily.

Single issue prices for *Clinical Infectious Diseases* are:

	EUR	GBP	USD
Institutional	€46	£38	\$49
Corporate	€57	£48	\$62
Personal	€15	£13	\$12

For annual subscription rates, please see [http://www.oxfordjournals.org/our\\_journals/cid/access\\_purchase/price\\_list.html](http://www.oxfordjournals.org/our_journals/cid/access_purchase/price_list.html).

Please note: UK£ rate applies to UK and Rest of World, except US and Canada (US\$) and Europe (Eur€).

Full prepayment in the correct currency is required for all orders. Payment should be in US dollars for orders being delivered to the USA or Canada; Euros for orders being delivered within Europe (excluding the UK); GBP Sterling for orders being delivered elsewhere (i.e., not being delivered to USA, Canada, or Europe). All orders should be accompanied by full payment and sent to your nearest Oxford Journals office. Subscriptions are accepted for complete volumes only. Orders are regarded as firm, and payments are not refundable. Our prices include dispatch by Standard Air. Claims must be notified within four months of dispatch/order date (whichever is later). Subscriptions in the EEC may be subject to European VAT. If registered, please supply details to avoid unnecessary charges. For subscriptions that include online versions, a proportion of the subscription price may be subject to UK VAT. Subscribers in Canada, please add GST to the prices quoted. Personal rate subscriptions are only available if payment is made by personal check or credit card, delivery is to a private address, and is for personal use only.

The current year and two previous years' issues are available from Oxford Journals. Previous volumes can be obtained from the Periodicals Service Company, 11 Main Street, Germantown, NY 12526, USA. E-mail: [psc@periodicals.com](mailto:psc@periodicals.com). Email: [psc@periodicals.com](mailto:psc@periodicals.com). Tel: (518) 537-4700. Fax: (518) 537-5899.

## Contact information

Journals Customer Service Department, Oxford Journals, Great Clarendon Street, Oxford OX2 6DP, UK. E-mail: [jnls.cust.serv@oup.com](mailto:jnls.cust.serv@oup.com). Tel: +44 (0)1865 353907. Fax: +44 (0) 1865 353485. **In the Americas, please contact:** Journals Customer Service Department, Oxford Journals, 2001 Evans Road, Cary, NC 27513, USA. E-mail: [jnldorders@oup.com](mailto:jnldorders@oup.com). Tel: (800) 852-7323 (toll-free in USA/Canada) or (919) 677-0977. Fax: (919) 677-1714. **In Japan, please contact:** Journals Customer Service Department, Oxford Journals, 4-5-10-8F Shiba, Minato-ku, Tokyo, 108-8386, Japan. E-mail: [custserv.jp@oup.com](mailto:custserv.jp@oup.com). Tel: (81) 3 5444 5858. Fax: (81) 3 3454 2929.

## Methods of payment

Payment should be made: by check (to Oxford Journals, Cashiers Office, Great Clarendon Street, Oxford, OX2 6DP, UK); by bank transfer [to Barclays Bank Plc, Oxford Office, Oxford (bank sort code 20-65-18) (UK); overseas only Swift code BARC GB22 (GB£ Sterling Account no. 70299332, IBAN GB89BARC20651870299332; US\$ Dollars Account no. 66014600, IBAN GB27BARC20651866014600; EU€ EURO Account no. 78923655, IBAN GB16BARC20651878923655)]; or by credit card (MasterCard, Visa, Switch, or American Express).

## Postal information

*Clinical Infectious Diseases* (ISSN: 1058-4838) is published semi-monthly by Oxford University Press, 2001 Evans Road, Cary, NC 27513-2009, USA. Periodicals Postage Paid at Cary, NC, and additional mailing offices. POSTMASTER: Send address changes to *Clinical Infectious Diseases*, Journals Customer Service Department, Oxford University Press, 2001 Evans Road, Cary, NC 27513-2009.

## Oxford Journals environmental and ethical policies

Oxford Journals, a division of Oxford University Press, is committed to working with the global community to bring the highest quality research to the widest possible audience. Oxford Journals will protect the environment by implementing environmentally friendly policies and practices wherever possible. Please see <http://www.oxfordjournals.org/ethicalpolicies.html> for further information on environmental and ethical policies.

## Digital object identifiers

For information on dois and to resolve them, please visit [www.doi.org](http://www.doi.org).

## Supplements, reprints, and corporate sales

For requests from industry and companies regarding supplements, bulk article reprints, sponsored subscriptions, translation opportunities for previously published material, and corporate online opportunities, please e-mail [special.sales@oup.com](mailto:special.sales@oup.com), Fax: +44 (0)1865 353774, or visit [www.oxfordjournals.org/sales](http://www.oxfordjournals.org/sales).

## Permissions

For information on how to request permissions to reproduce articles or information from this journal, please visit [www.oxfordjournals.org/permissions](http://www.oxfordjournals.org/permissions).

## Advertising

US advertising inquiries should be sent to Pharmaceutical Media, 30 East 33rd Street, New York, NY, 10016; Tel: 212-685-5010; Fax: 212-685-6126; <http://www.pminy.com>. International advertising inquiries should be sent to Advertising and Special Sales, Oxford Journals, Oxford University Press, Great Clarendon Street, Oxford, OX2 6DP, UK. Tel: +44 (0)1865 354767; Fax: +44 (0)1865 353774; E-mail: [jnlsadvertising@oup.com](mailto:jnlsadvertising@oup.com).

## Drug disclaimer

The mention of trade names, commercial products or organizations, and the inclusion of advertisements in the journal does not imply endorsement by the *Clinical Infectious Diseases*, the editors, the editorial board, Oxford University Press, or the organization to which the authors are affiliated. The editors and publishers have taken all reasonable precautions to verify drug names and doses, the results of experimental work, and clinical findings published in the journal. The ultimate responsibility for the use and dosage of drugs mentioned in the journal and in interpretation of published material lies with the medical practitioners, and the editors and publishers cannot accept liability for damages arising from any errors or omissions in the journal. Please inform the editors of any errors.

## Disclaimer

Statements of fact and opinion in the articles in *Clinical Infectious Diseases* are those of the respective authors and contributors and not of *Clinical Infectious Diseases* or Oxford University Press. Neither Oxford University Press nor *Clinical Infectious Diseases* make any representation, express or implied, in respect of the accuracy of the material in this journal and cannot accept any legal responsibility or liability for any errors or omissions that may be made. The reader should make her or his own evaluation as to the appropriateness or otherwise of any experimental technique described.

Copyright © 2016 by Oxford University Press on behalf of the Infectious Diseases Society of America.

## Indexing/Abstracting

All rights reserved; no part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission of the publisher or a license permitting restricted copying issued in the USA by the Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923.

## Instructions for authors

Full instructions for manuscript preparation and submission can be found at [http://www.oxfordjournals.org/our\\_journals/cid/for\\_authors.html](http://www.oxfordjournals.org/our_journals/cid/for_authors.html).

Typeset by Nova Techset Private Limited, Chennai, India.

Printed by Cenveo Publisher Services, Lancaster, PA, USA.

Oxford University Press is a department of the University of Oxford. It furthers the University's objective of excellence in research, scholarship, and education by publishing worldwide.

*An Official Publication of the Infectious Diseases Society of America and the HIV Medicine Association*

## **EDITOR**

Sherwood L. Gorbach

## **DEPUTY EDITOR**

Michael Barza

## **ASSISTANT DEPUTY EDITOR**

Sara E. Cosgrove

## **ASSOCIATE EDITORS**

Barbara D. Alexander  
Neil R. Blacklow  
Donald A. Goldmann  
Camilla S. Graham  
John R. Graybill  
Adolf W. Karchmer  
Jerome O. Klein  
Robert T. Schooley  
Cynthia L. Sears  
Lucy S. Tompkins  
Christine Wanke

## **COVER ART EDITORS**

Michael Grizzard  
Mary Grizzard

## **STATISTICAL EDITORS**

Norma Terrin  
Steven A. Cohen  
Farzad Noubary  
Victor De Gruttola

## **HISTOPATHOLOGY EDITORS**

Ann Marie Nelson  
Mary Klassen-Fischer

## **EDITORIAL OFFICE STAFF**

Carlos M. Terra,  
Managing Editor  
Claire R. Neumann,  
Acquisitions Editor  
Diana Cerrone,  
Manuscript Coordinator  
Blake Campbell,  
Editorial Office Assistant

## **SPECIAL SECTION EDITORS**

### ***Antimicrobial Resistance***

George M. Eliopoulos

### ***Book Reviews***

Gary P. Wormser

### ***Clinical Practice***

Ellie J. C. Goldstein

### ***Emerging Infections***

James M. Hughes  
Mary E. Wilson

### ***Food Safety***

Patricia M. Griffin

### ***Healthcare Epidemiology***

Robert A. Weinstein

### ***HIV/AIDS***

Kenneth H. Mayer

### ***Immunocompromised Hosts***

David R. Snyderman

## ***In the Literature***

Stan Deresinski

## ***Medical Microbiology***

L. Barth Reller  
Melvin P. Weinstein

## ***News***

Donald Kaye

## ***Photo Quiz/Arcanum***

Anthony Amoroso

## ***Quality Improvement***

Trish M. Perl

## ***Reviews of Anti-infective Agents***

Louis D. Saravolatz

## ***Vaccines***

Stanley Plotkin

## ***Viral Hepatitis***

Camilla S. Graham

## **PAST EDITORS**

### ***Reviews of Infectious Diseases***

Edward H. Kass, 1979–1989

(vols. 1–11)

Sydney M. Finegold, 1990–1991

(vols. 12 and 13)

### ***Clinical Infectious Diseases***

Sydney M. Finegold, 1992–1999

(vols. 14–29)

# Clinical Infectious Diseases

---

*An Official Publication of the Infectious Diseases Society of America and the HIV Medicine Association*

## EDITORIAL ADVISORY BOARD

Anucha Apisarnthanarak,  
Pratumthani, Thailand

Roberto Badaro,  
Salvador, Brazil

Carol J. Baker,  
Houston

Fernando Baquero,  
Madrid, Spain

John G. Bartlett,  
Baltimore

Stephen G. Baum,  
New York

John E. Bennett,  
Bethesda

Emilio Bouza,  
Madrid, Spain

Yehuda Carmeli,  
Tel Aviv, Israel

G. Ralph Corey,  
Durham

Erika M. C. D'Agata,  
Boston

Silvano Esposito,  
Naples, Italy

Javier Garau,  
Barcelona, Spain

Jose M. Gatell,  
Barcelona, Spain

M. Lindsay Grayson,  
Melbourne, Australia

James G. Hakim,  
Harare, Zimbabwe

Carol A. Kauffman,  
Ann Arbor

Keith Klugman,  
Atlanta

Umesh G. Laloo,  
Congella, South Africa

Stephen D. Lawn,  
Cape Town, South Africa

Catherine Leport,  
Paris, France

Daniel P. Lew,  
Geneva, Switzerland

Lionel A. Mandell,  
Hamilton, Canada

Jeanne M. Marrazzo,  
Seattle

Thomas J. Marrie,  
Edmonton, Canada

Daniel M. Musher,  
Houston

Carl Erik Nord,  
Stockholm, Sweden

Timothy Peto,  
Oxford, England

Didier Raoult,  
Marseille, France

Guillermo M. Ruiz-Palacios,  
Tlalpan, Mexico

Marisela Silva,  
Caracas, Venezuela

Vincent Soriano,  
Madrid, Spain

Soumya Swaminathan,  
Chennai, India

Joseph M. Vinetz,  
La Jolla

Gui-Qiang Wang,  
Beijing, China

Andreas F. Widmer,  
Basel, Switzerland

Kwok-yung Yuen,  
Hong Kong, China

Anita K. M. Zaidi,  
Karachi, Pakistan

Abigail D. Zuger,  
New York



Scan to view this journal on your mobile device.



1300 Wilson Blvd., Suite 300  
Arlington, VA 22209  
Telephone: (703) 299-0200  
Fax: (703) 299-0204  
E-mail: [info@idsociety.org](mailto:info@idsociety.org)  
URL: <http://www.idsociety.org>

BOARD OF DIRECTORS

EXECUTIVE COMMITTEE

Johan S. Bakken, President  
William G. Powderly, President-Elect  
Paul G. Auwaerter, Vice President  
Penelope H. Dennehy, Secretary  
Helen W. Boucher, Treasurer  
Stephen B. Calderwood, Immediate Past President

DIRECTORS

Barbara D. Alexander  
Henry F. Chambers  
Janet A. Englund  
Thomas Fekete  
Lawrence P. Martinelli  
Thomas A. Moore  
Trish M. Perl  
Steven K. Schmitt  
Judith A. Aberg (HIVMA Representative)  
Anthony Harris (SHEA Liaison)  
David W. Kimberlin (PIDS Liaison)  
Mark A. Leasure (Chief Executive Officer)

PUBLICATIONS COMMITTEE

Louis D. Saravolatz, Chair  
Mark DiNubile  
Hana El-Sahly  
Mathias Lichterfeld  
Aaron Milstone  
Michele I. Morris  
Cindy Taminga  
Yi-Wei Tang  
Harrys Torres  
Richard R. Watkins  
Sherwood L. Gorbach, Editor, *CID*  
Martin S. Hirsch, Editor, *JID*  
Paul E. Sax, Editor, *OFID*  
Penelope H. Dennehy (Board Liaison)  
Diana L. Olson (Vice President, Communications)



hiv medicine association

1300 Wilson Blvd., Suite 300  
Arlington, VA 22209  
Telephone: (703) 299-1215  
Fax: (703) 299-8766  
E-mail: [info@hivma.org](mailto:info@hivma.org)  
URL: <http://www.hivma.org>

BOARD OF DIRECTORS

EXECUTIVE COMMITTEE

Carlos del Rio, Chair  
Wendy Armstrong, Chair-Elect  
Rafael Campo, Vice-Chair  
Adaora Adimora, Immediate Past Chair

DIRECTORS

Joel Ang  
Stephen Boswell  
Judith Feinberg  
Lisa K. Fitzpatrick  
Donna Futterman  
Rajesh T. Gandhi  
Sally L. Hodder  
Carole A. Hohl  
Jeanne Keruly  
Renslow Sherer  
William Towner  
Rochelle Walensky  
Judith A. Aberg (IDSAs Representative)  
Andrea Weddle (Executive Director)



 Be part of the solution  
at IDWeek Town Hall →


## Table of Contents

Volume 62 Issue 9 May 1, 2016

For checked items

 view abstracts  download to citation manager  

### NEWS

#### 1 May News

Clin Infect Dis. (2016) 62 (9): i-ii doi:10.1093/cid/ciw089

[Extract](#) [FREE Full Text \(HTML\)](#) [View with LENS](#) [FREE Full Text \(PDF\)](#) [Permissions](#)

### IN THE LITERATURE

#### In the Literature

Clin Infect Dis. (2016) 62 (9): iii-iv doi:10.1093/cid/ciw070

[Extract](#) [FREE Full Text \(HTML\)](#) [View with LENS](#) [FREE Full Text \(PDF\)](#) [Permissions](#)

### ARTICLES AND COMMENTARIES

Yu-Hsiang Hsieh, Richard E. Rothman, Oliver B. Laeyendecker, Gabor D. Kelen, Ama Avornu, Eshan U. Patel, Jim Kim, Risha Irvin, David L. Thomas, and Thomas C. Quinn

#### Evaluation of the Centers for Disease Control and Prevention Recommendations for Hepatitis C Virus Testing in an Urban Emergency Department

Clin Infect Dis. (2016) 62 (9): 1059-1065 doi:10.1093/cid/ciw074

[Abstract](#) [Full Text \(HTML\)](#) [View with LENS](#) [Full Text \(PDF\)](#) [Permissions](#)

We assessed the burden of undocumented hepatitis C virus infection in emergency department patients prior to implementation of testing program. Our data suggest the need to consider expanding the current Centers for Disease Control and Prevention birth cohort–based testing in urban healthcare settings.

Michael S. Lyons, Vidhya A. Kunnathur, Susan D. Rouster, Kimberly W. Hart, Matthew I. Sperling, Carl J. Fichtenbaum, and Kenneth E. Sherman

#### Prevalence of Diagnosed and Undiagnosed Hepatitis C in a Midwestern Urban Emergency Department

Clin Infect Dis. (2016) 62 (9): 1066-1071 doi:10.1093/cid/ciw073

[Abstract](#) [Full Text \(HTML\)](#) [View with LENS](#) [Full Text \(PDF\)](#) [Permissions](#)


Prevalence of hepatitis C virus is remarkably high in emergency department populations, even in a region of the Midwest not characterized by high HIV prevalence. In this setting, many patients will be missed if using only the birth cohort screening approach.

Natasha K. Martin, Alicia Thornton, Matthew Hickman, Caroline Sabin, Mark Nelson, Graham S. Cooke, Thomas C. S. Martin, Valerie Delpech, Murad Ruf, Huw Price, Yusef Azad, Emma C. Thomson, and Peter Vickerman

#### Editor's Choice: Can Hepatitis C Virus (HCV) Direct-Acting Antiviral Treatment as Prevention Reverse the HCV Epidemic Among Men Who Have Sex With Men in the United Kingdom? Epidemiological and Modeling Insights

Clin Infect Dis. (2016) 62 (9): 1072-1080 doi:10.1093/cid/ciw075

[Abstract](#) [FREE Full Text \(HTML\)](#) [View with LENS](#) [FREE Full Text \(PDF\)](#) [Supplementary Data](#)

 OPEN ACCESS 

Epidemiological data and modeling suggest a continuing hepatitis C virus (HCV) epidemic among human immunodeficiency virus–diagnosed men who have sex with men in the United Kingdom. Substantial reductions in HCV transmission could be achieved through scale-up of HCV treatment and behavioral intervention.

Anne F. Luetkemeyer, Cynthia Firnhaber, Michelle A. Kendall, Xingye Wu, Gerald H. Mazurek, Debra A. Benator, Roberto Arduino, Michel Fernandez, Elizabeth Guy, Pamela Johnson, Beverly Metchock, Fred Sattler, Edward Telzak, Yun F. Wang, Marc Weiner, Susan Swindells, Ian M. Sanne, Diane V. Havlir, Beatriz Grinsztejn, and David Alland for the AIDS Clinical Trials Group A5295 and Tuberculosis Trials Consortium Study 34 Teams

#### Evaluation of Xpert MTB/RIF Versus AFB Smear and Culture to Identify Pulmonary Tuberculosis in Patients With Suspected Tuberculosis From Low and Higher Prevalence Settings

Clin Infect Dis. (2016) 62 (9): 1081-1088 doi:10.1093/cid/ciw035

[Abstract](#) [Full Text \(HTML\)](#) [View with LENS](#) [Full Text \(PDF\)](#) [Supplementary Data](#) [Permissions](#)

In the US, Xpert demonstrated excellent sensitivity in individuals with smear-positive tuberculosis and identified the majority with smear-negative tuberculosis. One Xpert predicted the absence of smear positive tuberculosis in 99.7% of specimens, indicating a role in respiratory isolation algorithms.

Andrew R. DiNardo, Christoph Lange, and Anna M. Mandalakas

#### Editorial Commentary: 1, 2, 3 (Years) ... and You're Out: The End of a 123-year

**Historic Era**

Clin Infect Dis. (2016) 62 (9): 1089-1091 doi:10.1093/cid/ciw041

[Extract](#) [Full Text \(HTML\)](#) [View with LENS](#) [Full Text \(PDF\)](#) [Permissions](#)

Carlos A. DiazGranados, Andrew J. Dunning, Corwin A. Robertson, H. Keipp Talbot, Victoria Landolfi, and David P. Greenberg

**Effect of Previous-Year Vaccination on the Efficacy, Immunogenicity, and Safety of High-Dose Inactivated Influenza Vaccine in Older Adults**

Clin Infect Dis. (2016) 62 (9): 1092-1099 doi:10.1093/cid/ciw085

[Abstract](#) [FREE Full Text \(HTML\)](#) [View with LENS](#) [FREE Full Text \(PDF\)](#) [Supplementary Data](#)  
OPEN ACCESS 

High-dose inactivated split-virus influenza vaccine showed higher immunogenicity and relative efficacy compared with standard-dose inactivated split-virus influenza vaccine, irrespective of type of vaccine used the preceding year. The safety profile was also unaffected by previous-year vaccine.

T. Roice Fulton, Varun K. Phadke, Walter A. Orenstein, Alan R. Hinman, Wayne D. Johnson, and Saad B. Omer

**Editor's Choice: Protective Effect of Contemporary Pertussis Vaccines: A Systematic Review and Meta-analysis**

Clin Infect Dis. (2016) 62 (9): 1100-1110 doi:10.1093/cid/ciw051

[Abstract](#) [FREE Full Text \(HTML\)](#) [View with LENS](#) [FREE Full Text \(PDF\)](#) [Supplementary Data](#) [Permissions](#)

In this meta-analysis of pertussis vaccine efficacy/effectiveness studies focusing on formulations currently on the market, the overall short-term (<3 years after completion of the primary series) protective effect against WHO-defined pertussis was lower for acellular vaccines than for whole-cell vaccines.

Erika Hammarlund, Archana Thomas, Elizabeth A. Poore, Jan J. Amanna, Abby E. Rynko, Motomi Mori, Zunqiu Chen, and Mark K. Slifka

**Durability of Vaccine-Induced Immunity Against Tetanus and Diphtheria Toxins: A Cross-sectional Analysis**

Clin Infect Dis. (2016) 62 (9): 1111-1118 doi:10.1093/cid/ciw066

[Abstract](#) [Full Text \(HTML\)](#) [View with LENS](#) [Full Text \(PDF\)](#) [Supplementary Data](#) [Permissions](#)

The persistence of vaccine-induced antibody responses to tetanus and diphtheria were studied in 546 adults. Immunity was long-lived in both men and women and remained durable regardless of advanced age, suggesting that the 10-year adult booster vaccination schedule be reexamined.

Sara Tomczyk, Ruth Lynfield, William Schaffner, Arthur Reingold, Lisa Miller, Susan Petit, Corinne Holtzman, Shelley M. Zansky, Ann Thomas, Joan Baumbach, Lee H. Harrison, Monica M. Farley, Bernard Beall, Lesley McGee, Ryan Gierke, Tracy Pondo, and Lindsay Kim

**Prevention of Antibiotic-Nonsusceptible Invasive Pneumococcal Disease With the 13-Valent Pneumococcal Conjugate Vaccine**

Clin Infect Dis. (2016) 62 (9): 1119-1125 doi:10.1093/cid/ciw067

[Abstract](#) [Full Text \(HTML\)](#) [View with LENS](#) [Full Text \(PDF\)](#) [Permissions](#)

We present the impact of 13-valent pneumococcal conjugate vaccine (PCV13) on antibiotic-nonsusceptible invasive pneumococcal disease. In 2009–2013, rates of serotypes included in PCV13 but not 7-valent PCV decreased; rates of non-PCV13 serotypes increased slightly, but no serotype dominated.

Xianding Deng, Gisele Peirano, Erin Schillberg, Tony Mazzulli, Scott D. Gray-Owen, John L. Wylie, D. Ashley Robinson, Salaheddin M. Mahmud, and Dylan R. Pillai

**Whole-Genome Sequencing Reveals the Origin and Rapid Evolution of an Emerging Outbreak Strain of *Streptococcus pneumoniae* 12F**

Clin Infect Dis. (2016) 62 (9): 1126-1132 doi:10.1093/cid/ciw050

[Abstract](#) [Full Text \(HTML\)](#) [View with LENS](#) [Full Text \(PDF\)](#) [Supplementary Data](#) [Permissions](#)

The Canadian pneumococcal 12F outbreak was caused by a novel strain that acquired macrolide resistance through horizontal gene transfer and developed fluorquinolone resistance via stepwise mutation. Rapid expansion of this clone in North America warrants heightened surveillance.

**VIEWPOINTS**Nathan C. Bahr, Suzaan Marais, Maxine Caws, Reinout van Crevel, Robert J. Wilkinson, Jaya S. Tyagi, Guy E. Thwaites, and David R. Boulware for the Tuberculous Meningitis International Research Consortium  
**GeneXpert MTB/Rif to Diagnose Tuberculous Meningitis: Perhaps the First Test but not the Last**

Clin Infect Dis. (2016) 62 (9): 1133-1135 doi:10.1093/cid/ciw083

[Abstract](#) [Full Text \(HTML\)](#) [View with LENS](#) [Full Text \(PDF\)](#) [Permissions](#)

Experts attending tuberculous meningitis meeting ask World Health Organization to revise current recommendations regarding tuberculous meningitis.

**BRIEF REPORTS**

Julianne R. Brown, Kimberly Gilmour, and Judith Breuer

**Norovirus Infections Occur in B-Cell-Deficient Patients**

Clin Infect Dis. (2016) 62 (9): 1136-1138 doi:10.1093/cid/ciw060

[Abstract](#) [Full Text \(HTML\)](#) [View with LENS](#) [Full Text \(PDF\)](#) [Supplementary Data](#) [Permissions](#)

Kim Y. Green

**Editorial Commentary: Noroviruses and B Cells**

Clin Infect Dis. (2016) 62 (9): 1139-1140 doi:10.1093/cid/ciw063

[Extract](#) [Full Text \(HTML\)](#) [View with LENS](#) [Full Text \(PDF\)](#) [Permissions](#)

## PHOTO QUIZ

### Progressive Right-Sided Hemiparesis in a Man With Sarcoidosis

*Clin Infect Dis.* (2016) 62 (9): 1141-1142 doi:10.1093/cid/ciw006

[Extract](#) [Full Text \(HTML\)](#) [View with LENS](#) [Full Text \(PDF\)](#) [Permissions](#)

## INVITED ARTICLES

### CLINICAL PRACTICE

Victor H. Matsubara, H. M. H. N. Bandara, Marcia P. A. Mayer, and Lakshman P. Samaranyake

#### Probiotics as Antifungals in Mucosal Candidiasis

*Clin Infect Dis.* (2016) 62 (9): 1143-1153 doi:10.1093/cid/ciw038

[Abstract](#) [Full Text \(HTML\)](#) [View with LENS](#) [Full Text \(PDF\)](#) [Permissions](#)

Probiotics have potential to be worthy allies in the battle against candidiasis. Their antifungal effect may be due to the suppression of candidal filamentation and biofilm formation. Data indicate that probiotics are useful prophylactic and adjunctive therapies against mucosal candidiasis.

### IMMUNOCOMPROMISED HOSTS

Anders Åsberg, Atul Humar, Halvor Rollag, Alan G. Jardine, Deepali Kumar, Pål Aukrust, Thor Ueland, Angelo A. Bignamini, and Anders Hartmann

#### Lessons Learned From a Randomized Study of Oral Valganciclovir Versus Parenteral Ganciclovir Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients: The VICTOR Trial

*Clin Infect Dis.* (2016) 62 (9): 1154-1160 doi:10.1093/cid/ciw084

[Abstract](#) [Full Text \(HTML\)](#) [View with LENS](#) [Full Text \(PDF\)](#) [Permissions](#)

In addition to showing noninferiority for oral valganciclovir compared with intravenous ganciclovir for treatment of cytomegalovirus (CMV) disease, the VICTOR biobank, in a series of post hoc analyses, provided clinically valuable insights into the treatment and pathogenesis of CMV disease.

### HIV/AIDS

Olivier Marcy, Vibol Ung, Sophie Goyet, Laurence Borand, Philippe Msellati, Mathurin Tejiokem, Ngoc Lan Nguyen Thi, Boubacar Nacro, Sokleaph Cheng, Sara Eyangoh, Thu Hang Pham, Abdoul-Salam Ouedraogo, Arnaud Tarantola, Sylvain Godreuil, Stéphane Blanche, and Christophe Delacourt for the PAANTHER study group

#### Performance of Xpert MTB/RIF and Alternative Specimen Collection Methods for the Diagnosis of Tuberculosis in HIV-Infected Children

*Clin Infect Dis.* (2016) 62 (9): 1161-1168 doi:10.1093/cid/ciw036

[Abstract](#) [Full Text \(HTML\)](#) [View with LENS](#) [Full Text \(PDF\)](#) [Supplementary Data](#) [Permissions](#)

The accuracy of Xpert MTB/RIF was similar on standard and alternative samples in 272 human immunodeficiency virus-infected children with suspected tuberculosis; its sensitivity on combined nasopharyngeal aspirate and stool samples (75.9%) was equivalent to that on standard samples.

Anne K. Detjen and Elisabetta Walters

#### Editorial Commentary: Improving Children's Access to New Tuberculosis Diagnostic Tools Starts With the Collection of Appropriate Specimens

*Clin Infect Dis.* (2016) 62 (9): 1169-1171 doi:10.1093/cid/ciw042

[Extract](#) [Full Text \(HTML\)](#) [View with LENS](#) [Full Text \(PDF\)](#) [Permissions](#)

David V. Glidden, K. Rivet Amico, Albert Y. Liu, Sybil G. Hosek, Peter L. Anderson, Susan P. Buchbinder, Vanessa McMahan, Kenneth H. Mayer, Burns David, Mauro Schechter, Beatriz Grinsztejn, Juan Guanira, and Robert M. Grant

#### Symptoms, Side Effects and Adherence in the iPrEx Open-Label Extension

*Clin Infect Dis.* (2016) 62 (9): 1172-1177 doi:10.1093/cid/ciw022

[Abstract](#) [Full Text \(HTML\)](#) [View with LENS](#) [Full Text \(PDF\)](#) [Permissions](#)

The start-up syndrome associated with initiation of truvada as pre-exposure prophylaxis peaks within the first month of use and resolves by the third month. It is experienced by 16% of users and has a modest effect on adherence.

Rodolphe Thiébaud, Ana Jarne, Jean-Pierre Routy, Irini Sereti, Margaret Fischl, Prudence Ive, Roberto F. Speck, Gianpiero D'Offizi, Salvatore Casari, Daniel Commenges, Sharné Foulkes, Ven Natarajan, Thérèse Croughs, Jean-François Delfraissy, Guiseppe Tambussi, Yves Levy, and Michael M. Lederman

#### Repeated Cycles of Recombinant Human Interleukin 7 in HIV-Infected Patients With Low CD4 T-Cell Reconstitution on Antiretroviral Therapy: Results of 2 Phase II Multicenter Studies

*Clin Infect Dis.* (2016) 62 (9): 1178-1185 doi:10.1093/cid/ciw065

[Abstract](#) [Full Text \(HTML\)](#) [View with LENS](#) [Full Text \(PDF\)](#) [Supplementary Data](#) [Permissions](#)

In 2 phase II trials, repeated cycles of recombinant human interleukin 7 were safe and led to a sustained increase in CD4 T-cell counts in human immunodeficiency virus-infected individuals with low CD4 T-cell reconstitution during antiretroviral therapy.

## ANSWER TO THE PHOTO QUIZ

### Progressive Right-Sided Hemiparesis in a Man With Sarcoidosis

*Clin Infect Dis.* (2016) 62 (9): 1186-1187 doi:10.1093/cid/ciw011



[Extract](#) [Full Text \(HTML\)](#) [View with LENS](#) [Full Text \(PDF\)](#) [Permissions](#)

## CORRESPONDENCE

Wuelton M. Monteiro, José P. Moura-Neto, Judith Recht, Quique Bassat, and Marcus V. G. Lacerda  
**Fatal Primaquine-Induced Hemolysis in a Patient With *Plasmodium vivax* Malaria and G6PD A(-) Variant in the Brazilian Amazon**

*Clin Infect Dis.* (2016) 62 (9): 1188 doi:10.1093/cid/ciw039

[Extract](#) [Full Text \(HTML\)](#) [View with LENS](#) [Full Text \(PDF\)](#) [Permissions](#)

Simon Tiberi, Giovanni Sotgiu, Lia D'Ambrosio, Rosella Centis, Marcos Abdo Arbex, Edith Alarcon Arrascaue, Jan Willem Alffenaar, Jose A. Caminero, Mina Gaga, Gina Gualano, Alena Skrahina, Ivan Solovic, Giorgia Sulis, Marina Tadolini, Valentina Alarcon Guizado, Saverio De Lorenzo, Aurora Jazmin Roby Arias, Anna Scardigli, Onno W. Akkerman, Alena Aleksa, Janina Artsukevich, Vera Avchinko, Eduardo Henrique Bonini, Félix Antonio Chong Marin, Lorena Collahuazo López, Gerard de Vries, Simone Dore, Heinke Kunst, Alberto Matteelli, Charalampos Moschos, Fabrizio Palmieri, Apostolos Papavasileiou, Marie-Christine Payen, Andrea Piana, Antonio Spanevello, Dante Vargas Vasquez, Pietro Viggiani, Veronica White, Alimuddin Zumla, and Giovanni Battista Migliori

**Effectiveness and Safety of Imipenem–Clavulanate Added to an Optimized Background Regimen (OBR) Versus OBR Control Regimens in the Treatment of Multidrug–Resistant and Extensively Drug–Resistant Tuberculosis**

*Clin Infect Dis.* (2016) 62 (9): 1188–1190 doi:10.1093/cid/ciw088

[Extract](#) [Full Text \(HTML\)](#) [View with LENS](#) [Full Text \(PDF\)](#) [Permissions](#)

Gerd Fätkenheuer and Norma Jung

**Treatment of Asymptomatic Bacteriuria**

*Clin Infect Dis.* (2016) 62 (9): 1190 doi:10.1093/cid/ciw054

[Extract](#) [Full Text \(HTML\)](#) [View with LENS](#) [Full Text \(PDF\)](#) [Permissions](#)

Tommaso Cai and Riccardo Bartoletti

**Reply to Fätkenheuer and Jung**

*Clin Infect Dis.* (2016) 62 (9): 1191 doi:10.1093/cid/ciw057

[Extract](#) [Full Text \(HTML\)](#) [View with LENS](#) [Full Text \(PDF\)](#) [Permissions](#)

James C. Hurley

**Prophylactic Antibiotics for Severe Burns: Are They Safe?**

*Clin Infect Dis.* (2016) 62 (9): 1191–1193 doi:10.1093/cid/ciw053

[Extract](#) [Full Text \(HTML\)](#) [View with LENS](#) [Full Text \(PDF\)](#) [Supplementary Data](#) [Permissions](#)

Takashi Tagami and Hideo Yasunaga

**Reply to Hurley**

*Clin Infect Dis.* (2016) 62 (9): 1193 doi:10.1093/cid/ciw056

[Extract](#) [Full Text \(HTML\)](#) [View with LENS](#) [Full Text \(PDF\)](#) [Permissions](#)

Sarah R. Deeny, Colin J. Worby, Olga Tosas Auguet, Ben S. Cooper, Jonathan Edgeworth, Barry Cookson, and Julie V. Robotham

**More Research Is Needed to Quantify Risks, Benefits, and Cost–Effectiveness of Universal Mupirocin Usage**

*Clin Infect Dis.* (2016) 62 (9): 1193–1194 doi:10.1093/cid/ciw077

[Extract](#) [Full Text \(HTML\)](#) [View with LENS](#) [Full Text \(PDF\)](#) [Permissions](#)

David J. Hetem, Martin C. J. Bootsma, and Marc J. M. Bonten

**Reply to Deeny et al**

*Clin Infect Dis.* (2016) 62 (9): 1194–1195 doi:10.1093/cid/ciw079

[Extract](#) [Full Text \(HTML\)](#) [View with LENS](#) [Full Text \(PDF\)](#) [Permissions](#)

## COVER/STANDING MATERIAL

### Cover

*Clin Infect Dis.* (2016) 62 (9): NP doi:10.1093/cid/civ1049

[Full Text \(PDF\)](#) [Permissions](#)

### Editorial Advisory Board

*Clin Infect Dis.* (2016) 62 (9): NP doi:10.1093/cid/civ1073

[Full Text \(PDF\)](#) [Permissions](#)

### Editorial Board

*Clin Infect Dis.* (2016) 62 (9): NP doi:10.1093/cid/civ1097

[Full Text \(PDF\)](#) [Permissions](#)

### Subscriptions Page

*Clin Infect Dis.* (2016) 62 (9): NP doi:10.1093/cid/civ1145

[Full Text \(PDF\)](#) [Permissions](#)

**Masthead**

[Clin Infect Dis](#), (2016) 62 (9): NP doi:10.1093/cid/civ1121

[Full Text \(PDF\)](#) [Permissions](#)

**Table of Contents**

[Clin Infect Dis](#), (2016) 62 (9): NP doi:10.1093/cid/civ1169

[Full Text \(PDF\)](#) [Permissions](#)

For checked items

view abstracts  download to citation manager

Online ISSN 1537-6591 - Print ISSN 1058-4838

Copyright © 2016 [Infectious Diseases Society of America](#)

[Site Map](#) [Privacy Policy](#) [Cookie Policy](#) [Legal Notices](#) [Frequently Asked Questions](#)

Other Oxford University Press sites:

